Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

Metabolon Launches Strategic Outsourcing Programs Focused On Disease Metabolism

Published: Monday, October 15, 2012
Last Updated: Monday, October 15, 2012
Bookmark and Share
Metabolon’s partners will collaborate toward shared objectives through this program.

Metabolon, Inc. has announces the launch of its Disease Metabolism Strategic Outsourcing Program.

Through this program, Metabolon’s partners will collaborate toward shared objectives such as identifying novel targets, establishing high resolution phenotypic screening platforms, elucidating drug mechanism of action, discovering and validating pharmacodynamic biomarkers for translation to the clinic and for patient stratification.

Partners will have access to dedicated scientific, technical and IT staff at Metabolon, along with the company’s proprietary disease ontologies, as well as supporting visualization tools for the integration of metabolomics data with existing or data derived from such disciplines as genomics and proteomics.

John Ryals, Metabolon President and CEO, said, “We are excited to launch our Strategic Outsourcing Program as it represents a step change in the way the industry will think about and use metabolomics. This initiative results from years of research and development at Metabolon and has been requested by our industrial clients to fully exploit the potential of our platform. We believe that integrating metabolomic profiling deeply at the various stages of the R&D trajectory will lead to better targets, higher quality molecules, faster time to the clinic and reduced R&D risk and cost.”

Metabolon has completed hundreds of projects including those in oncology and metabolic disorders, and has acquired vast institutional knowledge of the metabolic pathways and targets that are involved in the onset of disease and its progression.

This new program offers a turnkey metabolism center of excellence that provides pharmaceutical and biotech partners access to the most advanced metabolomics research platforms, which serve to enhance their drug discovery and development efficiency.

Metabolon’s platform yields actionable insight into key disease metabolic processes, drug action, and patient response.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Metabolon Awarded Patent for Metabolomics Software
Visual PHIL™ Provides Visual Display of Complex Metabolomic Data
Tuesday, October 28, 2008
Scientific News
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Chemical Design Made Easier
Rice University scientists prepare elusive organocatalysts for drug and fine chemical synthesis.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Giant Molecules Inhibit Ebola Infection
European researchers have designed a "giant" molecule formed by thirteen fullerenes covered by carbohydrates which, by blocking this receptor, are able to inhibit the cell infection by an artificial ebola virus model.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Fighting Pain with Ketamine
Researchers at the Texas A&M Health Science Center are using ketamine, a drug that already exists as an anesthetic, to treat pain.
Possible New Treatment for Neurodegenerative Diseases Found
Researchers at the University of Liverpool have found that a well-established anti-epileptic drug could also be used as a treatment for neurodegenerative diseases.
Breast Cancer Drug Beats Superbug
Tamoxifen helps white blood cells clear multidrug-resistant bacteria in lab and mouse studies.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos